文献速递皮肤肿瘤

致癌性KIT诱导复制应激并赋予黑色素瘤细胞周期检查点脆弱性

Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma.
PubMed 文献 · J Invest Dermatol · 2021-10-21

肢端和黏膜黑色素瘤比常见皮肤黑色素瘤死亡率更高且KIT改变更多,KIT突变黑色素瘤治疗耐药。研究者用小鼠mKITK641E细胞建立同种移植模型,发现其增殖更快、染色体畸变更大、成瘤性更强,并筛选199种激酶抑制剂发现Chk1/ATR抑制的选择性脆弱性,机制与KITK641E诱导复制应激增加相关。

要点

  • KITK641E激活突变驱动黑色素瘤细胞转化、增殖和成瘤。
  • KITK641E细胞对Chk1/ATR抑制剂存在选择性脆弱性。
  • KITK641E诱导复制应激增加,提示新的治疗策略。

核心结论

  • KITK641E激活突变诱导复制应激增加,并赋予黑色素瘤细胞对Chk1/ATR抑制的选择性脆弱性。

研究设计与样本

  • 研究使用携带人类KITK642E激活突变对应的小鼠mKITK641E细胞,在免疫健全C57BL/6J小鼠中建立同种移植模型。
  • 研究对mKITK641E细胞进行了199种激酶抑制剂的筛选。

主要发现

  • mKITK641E细胞在体外显示转化特征,在免疫健全C57BL/6J小鼠中具有致瘤性。
  • 与载体对照细胞相比,mKITK641E细胞增殖更快、染色体畸变更大、三维球体扩增和侵袭性肿瘤生长更强。
  • 遗传和药理学抑制均验证了这些细胞对KITK641E的功能依赖性。
  • 激酶抑制剂筛选鉴定出KITK641E激活细胞对Chk1/ATR抑制的选择性脆弱性。
  • 机制上,KITK641E诱导的复制应激水平显著高于小鼠载体对照细胞。

临床怎么用

  • KIT突变黑色素瘤可考虑Chk1/ATR抑制剂作为潜在治疗策略。
  • 该同种移植模型可用于KIT驱动黑色素瘤的治疗策略研究。

局限性

  • 研究基于小鼠同种移植模型,尚未在人体中验证。
  • Chk1/ATR抑制的治疗策略需进一步临床前和临床研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acral and mucosal melanomas arise from sun-protected sites, disproportionately impact darker-skinned individuals, and exact higher mortality than common types of cutaneous melanoma. Genetically, acral and mucosal melanomas harbor more alterations of KIT than typical cutaneous melanomas. Because KIT-mutated melanomas remain largely treatment resistant, we set out to create a faithful murine KIT-driven allograft model to define newer therapeutic strategies. Using the prevalent human KITK642E activating mutation, the murine mKITK641E cellular avatars show features of transformation in vitro and tumorigenicity in immunocompetent C57BL/6J mice. mKITK641E cells proliferate more rapidly, exhibit greater chromosomal aberrations, and sustain three-dimensional spheroid expansion and aggressive tumor growth in C57BL/6J mice compared with their vector-controlled cells. We further verified the functional dependence of these cells on KITK641E with both genetic and pharmacologic suppression. Using these cells, we performed a screen of 199 kinase inhibitors and identified a selective vulnerability to Chk1/ATR inhibition in the KITK641E-activated cells. Mechanistically, we subsequently showed that KITK641E induces a significantly increased level of replication stress compared with murine vector‒controlled cells. These results showcase an allograft model of human KIT-driven melanomas, which uncovered an unappreciated role for replication stress in KIT melanomagenesis and implicated a possible therapeutic strategy with Chk1/ATR inhibitors.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Njauw CN, Ji Z, Pham DM, et al. Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. J Invest Dermatol. 2021. PMID: 34687746. doi:10.1016/j.jid.2021.07.188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。